Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the safety of lengthening the adalimumab dosing interval from 2 to 3 weeks, in patients with Crohn's disease or ulcerative colitis in long term (6 months) remission.
Critère d'inclusion
- inflammatory bowel disease